Testicular cancer commonly affects men aged between 20 and 35 years. It accounts up to 2% of cancers diagnosed in men, although the lifetime risk of mortality is less than 1%. Screening for testicular cancer is commonly performed by physician, who performs a physical examination, or self-examination by the patient. However, there is little evidence that documents the accuracy of such examinations. This review identified that no randomised controlled trials have been performed to evaluate the effectiveness of screening for testicular cancer. In the absence of high quality evidence, male patients with an increased risk of developing testicular cancer should be informed of the potential benefits and harms associated with screening.